On the cusp.
A nice short week then into May. Poised to run......
"Sofpironium bromide stands out as a novel “soft anti-cholinergic” developed by BLI, marking a significant advancement in hyperhidrosis treatment. Licensed to Fresh Tracks Therapeutics in 2012 and recently acquired by Botanix Pharmaceuticals, sofpironium bromide (SofdraTM) is on the cusp of FDA approval, anticipated in mid-2024. Already a success in Japan as ECCLOCK®, the drug is poised for further market expansion in South Korea through a partnership with Dong Wha Pharmaceutical."
On the cusp. A nice short week then into May. Poised to...
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
35.0¢ |
Change
0.020(6.06%) |
Mkt cap ! $551.2M | |||
| Open | High | Low | Value | Volume |
| 34.5¢ | 35.5¢ | 34.0¢ | $2.264M | 6.532M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 142195 | 34.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 35.0¢ | 447376 | 8 |
View Market Depth
| Last trade - 11.25am 17/06/2024 (20 minute delay) ? |
|
|||||
|
Last
34.8¢ |
Change
0.020 ( 6.17 %) |
||||
| Open | High | Low | Volume | ||
| 34.5¢ | 35.3¢ | 34.0¢ | 3788060 | ||
| Last updated 11.48am 17/06/2024 ? | |||||
| BOT (ASX) Chart |
